Application of bone absorption marker CTX in abnormal glucose metabolism occurrence prediction system

Abstract

The invention discloses application of a bone absorption marker CTX in an abnormal glucose metabolism occurrence prediction system. The prediction system comprises a base line bone absorption maker CTX variable input sub module and an analysis module, wherein the analysis module can build a tertile group on the basis of a variable input by the base line bone absorption marker CTX variable input sub module; the abnormal glucose metabolism occurrence risk of the base line CTX middle tertile people group is the lowest; the abnormal glucose metabolism occurrence risk of the base line CTX highest tertile people group is the highest. The prediction system has the advantages that the great guidance significance is realized on the use of anti-bone-absorption medicines on the treatment of high-riskpeople groups with osteoporosis accompanied with or not accompanied with diabetes. The bone absorption of the patient with osteoporosis is positively reduced; meanwhile, the glucose metabolism effectis considered; the bone absorption activity cannot be excessively reduced.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to the application of a bone resorption marker CTX in a system for predicting the occurrence of abnormal glucose metabolism. Background technique [0002] Diabetes is a global health problem. Epidemiological data show that prediabetes accounts for 30-50% of the total population, and 20-25% of people with normal glucose metabolism will develop prediabetes or diabetes within 10 years, so the prevention and control of diabetes and abnormal glucose metabolism is very necessary. So far, no clear research has found drugs that can effectively reduce the occurrence of diabetes. Diabetes and osteoporosis are both high-incidence diseases of the elderly. Research on the mutual regulation of bone metabolism and glucose metabolism has attracted more and more attention. The study of the interaction between the two is conducive to guiding clinical medication. [0003] Based on bones, studies have fo...

AI Technical Summary

Problems solved by technology

Population cross-sectional studies have confirmed that serum OCN is negatively correlated with fasting blood glucose (FPG) and glycosylated hemoglobin (HbA1c) (Liu, D.M., X.Z.Guo, H.J.Tong, et al., Association between osteocalcinandglucose metabolism: a meta-analysis.Osteoporos Int, 2015.26(12): 2823-33.), however, the follow-up data do not fully support the protective effect between low serum osteocalcin and the occurrence of diabetes, and some articles even believe that there is no correlation between OCN and the occurrence of diabetes (Hwang, Y.C. , J.H.Jee, I.K.Jeong, al., Circulating osteocalcin l vel is not associated with incident type 2diabetes in middle-aged male subjects: mean 8.4-year retrospective follow-up study Diabetes Care, 2012.35(9): 1919-24.Zwakenberg, S.R., C.M.Gundb rg, A.M.Spijkerman, et al., Osteocalcin Is Not Associated with the Risk of Type 2Diabetes: Findings from the EPIC-NL Study. PLoS One, 2015.10(9):e0138693.), there may be other molecular mechanisms mediating The role of bones in regulating blood sugar

Images